Clearmind Medicine Convenes Inaugural Scientific Advisory Board
Ticker: CMND · Form: 6-K · Filed: Sep 25, 2025 · CIK: 1892500
Sentiment: neutral
Topics: psychedelic-therapies, scientific-advisory-board, R&D
TL;DR
Clearmind Medicine just held its first SAB meeting to push psychedelic therapies forward.
AI Summary
Clearmind Medicine Inc. announced on September 25, 2025, that it convened its inaugural Scientific Advisory Board meeting. This meeting is a key step in advancing the company's psychedelic-derived therapies. The board will provide expert guidance on the company's research and development pipeline.
Why It Matters
The formation and meeting of a Scientific Advisory Board signifies a commitment to rigorous scientific development, potentially accelerating the path to clinical trials and regulatory approval for novel therapies.
Risk Assessment
Risk Level: medium — The company is in the early stages of developing novel therapies, which carries inherent scientific and regulatory risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- September 25, 2025 (date) — Date of press release and meeting
FAQ
What is the primary purpose of Clearmind Medicine's Scientific Advisory Board?
The Scientific Advisory Board is convened to provide expert guidance and advance the company's psychedelic-derived therapies.
When was the inaugural Scientific Advisory Board meeting held?
The inaugural Scientific Advisory Board meeting was held on September 25, 2025.
What type of therapies is Clearmind Medicine developing?
Clearmind Medicine is developing psychedelic-derived therapies.
What form is Clearmind Medicine filing with the SEC?
Clearmind Medicine Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Where is Clearmind Medicine Inc. headquartered?
Clearmind Medicine Inc. is headquartered at 101 - 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-09-25 07:56:21
Filing Documents
- ea0258751-6k_clearmind.htm (6-K) — 10KB
- ea025875102ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-091376.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: September 25, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3